Inozyme Pharma

As 2024 comes to a close, we want to take a moment to celebrate our employee resource group, Women in Progress (WiP), for their outstanding contributions to our company culture. Led by Natalie Conklin, Caitlin DeCandia, MBA, and Katie Swanner, PharmD, WiP is a supportive community of women and allies committed to advancing women's professional growth. This year, they hosted workshops on self-advocacy and male allyship, launched a mentorship program, volunteered at Women's Lunch Place, attended the Massachusetts Conference for Women, and so much more. Take a look back at our #WomenInProgress 👏   #WiP #CompanyCulture #Empowerment

From everyone at Inozyme Pharma, we’d like to wish you very Happy Holidays and all the best for the New Year!    #HappyHolidays #SeasonsGreetings

Thank you Christine O'Brien and Liz Molloy for sharing the important work you do at GACI Global to advance the development of treatments and support families across the world with our team. We’re grateful that you could spend time with us; your work inspires us every day. #ABCC6 #ENPP1 #GACI #Patientadvocacy

Our Senior Vice President and Chief Operating Officer Matt Winton, Ph.D., will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, 2024 from 2:30 - 2:55 p.m. ET. Learn more: https://bit.ly/41dd7Eo #Biotech #Biopharmaceutical

Thank you Nephrology Times and Sagar Nigwekar for this in-depth discussion of calciphylaxis, patient care and the results of the SEAPORT 1 trial from #KidneyWk    #Calciphylaxis #Nephrology #RareDisease

#HappyThanksgiving! Wishing everyone a safe, healthy and happy holiday!

Next week, we’ll be attending the Stifel 2024 Healthcare Conference in New York and the Jefferies London Healthcare Conference. Our CEO and Chairman, Doug Treco, Ph.D., will share our story and progress during presentations at both conferences. Learn more: https://bit.ly/3UNZ04h   #RareDisease #Biotech  

Today, we reported our Q3 2024 financial results and business highlights. Our lead candidate, INZ-701, continues to make important progress across several indications, and we shared new data highlighting its potential in serious disease affecting bone health and blood vessel function.   We are on track for several clinical milestones before the end of the year as we continue to work to bring new treatment options to these patients.   Learn more: https://bit.ly/4fuCbdR   #RareDisease #Biotech #ENPP1 #ABCC6 #Calciphylaxis

This week our team had the privilege of welcoming a mother whose children live every day with #ABCC6Deficiency, a rare disease for which we’re working to develop a first-in-class treatment. Hearing firsthand about the challenges her family faces, the resilience of her children, and the impact this disease has on their daily lives brought into focus the reason we push forward through the challenges of drug development. Creating new therapies is an incredibly complex, lengthy, and rigorous journey, especially for rare diseases, where science must often break new ground. Collaborating closely with patients and families is not only essential for our science but also a powerful reminder of why we’re here—to bring hope where there currently is none. Thank you to this remarkable mom for sharing her family’s story, her kind note (an excerpt is shown below), and for reinforcing our commitment to making a meaningful difference. And thank you to the dedicated team at Inozyme Pharma, who work tirelessly every day to turn hope into real, life-changing possibilities. Together we will continue to advance innovation and work toward a better future for patients everywhere. #RareDisease #PatientImpact #Innovation #Community #ABBC6 #ENPP1 #Team #GACIGlobal

Thank you Brian Orelli, PhD and BiotechTV for discussing #calciphylaxis and the latest INZ-701 data with Dr. Sagar Nigwekar M.D., Co-Director of the Kidney Research Center at Massachusetts General Hospital and our CSO Yves Sabbagh, PhD at #Kidneywk.   We look forward to continuing to build on these encouraging results, which provide a strong foundation for advancing INZ-701 into a registrational trial in calciphylaxis.   #RareDisease #ASN2024